Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 17;66(9):1470-1474.
doi: 10.1093/cid/cix1127.

Busting the Myth of "Static vs Cidal": A Systemic Literature Review

Affiliations

Busting the Myth of "Static vs Cidal": A Systemic Literature Review

Noah Wald-Dickler et al. Clin Infect Dis. .

Abstract

We sought to determine if clinical data validate the dogma that bactericidal antibiotics are more clinically effective than bacteriostatic agents. We performed a systematic literature review of published, randomized, controlled trials (RCTs) that compared a bacteriostatic agent to a bactericidal agent in the treatment of clinical, bacterial infections. Of 56 identified trials published since 1985, 49 found no significant difference in efficacy between bacteriostatic and bactericidal agents. In 6 trials it was found that the bacteriostatic agent was superior to the bactericidal agent in efficacy. Only 1 trial found that the bactericidal agent was superior; in that case, the inferiority of the static agent was explainable by underdosing of the drug based on pharmacokinetic-pharmacodynamic analysis. Thus, virtually all available data from high-quality, RCTs demonstrate no intrinsic superiority of bactericidal compared to bacteriostatic agents. Other drug characteristics such as optimal dosing, pharmacokinetics, and tissue penetration may be more important efficacy drivers.

PubMed Disclaimer

Comment in

  • Static vs Cidal Antibiotics.
    Steigbigel RT, Steigbigel NH. Steigbigel RT, et al. Clin Infect Dis. 2019 Jan 7;68(2):351-352. doi: 10.1093/cid/ciy645. Clin Infect Dis. 2019. PMID: 30099494 No abstract available.
  • Reply to Steigbigel and Steigbigel.
    Wald-Dickler N, Holtom P, Spellberg B. Wald-Dickler N, et al. Clin Infect Dis. 2019 Jan 7;68(2):352-353. doi: 10.1093/cid/ciy646. Clin Infect Dis. 2019. PMID: 30099501 No abstract available.

References

    1. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004; 38:864–70. - PubMed
    1. Freire AT, Melnyk V, Kim MJ et al. ; 311 Study Group Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140–51. - PubMed
    1. Bhavnani SM, Rubino CM, Hammel JP et al. . Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 2012; 56:1065–72. - PMC - PubMed
    1. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57:1756–62. - PMC - PubMed
    1. Breedt J, Teras J, Gardovskis J et al. ; Tigecycline 305 cSSSI Study Group Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658–66. - PMC - PubMed

Publication types

MeSH terms

Substances